Since the company’s inception, Tetraphase has developed a robust antibiotics platform based on the tetracycline core chemical structure, which offers the potential to dramatically improve the treatment of serious bacterial infections. Tetraphase has utilized this fully-synthetic chemistry technology to create a pipeline of novel tetracycline antibiotics, particularly those with activity against the toughest multidrug-resistant Gram-negative bacteria.

$ 5.95 +0.28 (4.94%)
Day High: 6.01
Day Low:  5.54
Volume:    1,813,695
4:00 PM ET
Aug 22, 2017

Delayed ~20 min., by eSignal.

Press Releases

Events & Presentations